UNSPSC 51111648: Oteracil

This classification denotes a pyrimidine antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5VT6420TIG. European Medicines Agency schedules Oteracil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB30899. Oteracil generally arises in the molecular formula C4H3N3O4. The term OTERACIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 no. 3, 1999, list 42.) Most nations schedule oteracil under HS 29336980 and SITC 51576.

As of Q4 2014, OTERACIL remains the US FDA Preferred Term for this commodity. Oteracil bears US NLM identifiers UMLS ID C0030032 and NCI Concept Code C76917. SMILES: C1(=NC(=O)NC(=O)N1)C(=O)[O-].[K+].

UNSPSC 51111648 Oteracil is a Commodity code for a pharmaceutical product — specifically, potassium sorbate salt used in oncology treatment — that state and local health agencies and correctional departments procure through pharmaceutical supply contracts and formulary agreements. State and local governments do not typically issue standalone solicitations for individual active pharmaceutical ingredients; instead, they procure oteracil as part of broader pharmacy benefit agreements, group purchasing organization (GPO) contracts, or state Medicaid formularies negotiated centrally by pharmacy directors or purchasing cooperatives. The product appears in procurement systems when state health departments, state Medicaid agencies, county hospitals, city health clinics, and correctional health systems add it to approved drug lists or execute multi-line pharmaceutical supply contracts that include it by NDC (National Drug Code) or generic classification.

The recent-opportunities block contains no recent state and local contract solicitations tagged with UNSPSC 51111648. This code sees minimal standalone procurement activity at the state and local level; oteracil purchases flow through pre-existing pharmaceutical supply agreements and formulary management vehicles rather than through stand-alone RFPs, RFQs, or ITBs. Business development professionals should monitor state Medicaid agency RFPs for pharmacy benefit management contracts and state health department cooperative purchasing announcements, which may embed oteracil procurement, but should not expect dedicated solicitation activity under this code.